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Highlights 
 Stimulated CGRP release was measured as an index of neuronal sensitivity.
 Paclitaxel attenuates phorbol ester- and TRPV1-stimulated release.
 Paclitaxel inhibits cPKC activity to elicit changes in stimulated release.
 Paclitaxel attenuates phorbol ester-stimulated cPKC membrane translocation.
 Paclitaxel does not affect basal cPKC expression, phosphorylation or localization.
Abstract 
Peripheral neuropathy is a dose-limiting and debilitating side effect of the chemotherapeutic 
drug, paclitaxel. Consequently, elucidating the mechanisms by which this drug alters sensory 
neuronal function is essential for the development of successful therapeutics for peripheral 
neuropathy. We previously demonstrated that chronic treatment with paclitaxel (3-5 days) 
ACCEPTED MANUSCRIPT
_________________________________________________________________________________
 
This is the author's manuscript of the article published in final edited form as:
Darby, L. M., Meng, H., & Fehrenbacher, J. C. (2017). Paclitaxel inhibits the activity and membrane localization of 
PKCα and PKCβI/II to elicit a decrease in stimulated calcitonin gene-related peptide release from cultured sensory 
neurons. Molecular and Cellular Neuroscience. https://doi.org/10.1016/j.mcn.2017.04.001
AC
CE
PT
ED
 M
AN
US
CR
IPT
reduces neuropeptide release stimulated by agonists of TRPV1. Because the activity of TRPV1 
channels is modulated by conventional and novel PKC isozymes (c/nPKC), we investigated 
whether c/nPKC mediate the loss of neuropeptide release following chronic treatment with 
paclitaxel (300 nM; 3 and 5 days). Release of the neuropeptide, calcitonin gene-related peptide 
(CGRP), was measured as an index of neuronal sensitivity. Following paclitaxel treatment, 
cultured dorsal root ganglia sensory neurons were stimulated with a c/nPKC activator, phorbol 
12,13-dibutyrate (PDBu), or a TRPV1 agonist, capsaicin, in the absence and presence of 
selective inhibitors of conventional PKCα and PKCβI/II isozymes (cPKC). Paclitaxel (300nM; 3 
days and 5 days) attenuated both PDBu- and capsaicin-stimulated release in a cPKC-
dependent manner. Under basal conditions, there were no changes in the protein expression, 
phosphorylation or membrane localization of PKC α, βI or βII, however, paclitaxel decreased 
cPKC activity as indicated by a reduction in the phosphorylation of cPKC substrates. Under 
stimulatory conditions, paclitaxel attenuated the membrane translocation of phosphorylated 
PKC α, βI and βII, providing a rationale for the attenuation in PDBu- and capsaicin-stimulated 
release. Our findings suggest that a decrease in cPKC activity and membrane localization are 
responsible for the reduction in stimulated peptide release following chronic treatment with 
paclitaxel in sensory neurons. 
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Pac, paclitaxel; c/nPKC, conventional and novel PKC isozymes; cPKC, conventional PKC 
isozymes; DRG, dorsal root ganglia; TRPV1, Transient Receptor Potential Vanilloid 1; CGRP, 
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calcitonin gene-related peptide; PDBu, phorbol 12,13-dibutyrate; BCTC, 4-(3-Chloro-2-
pyridinyl)-N-[4-(1,1-dimethylethyl)phenyl]-1-piperazinecarboxamide; MPL, methylpyrrolidone  
 
1. Introduction 
Paclitaxel is a microtubule stabilizing agent that is used to treat solid tumors including 
breast, ovarian and non-small cell lung cancer (Schiff and Horwitz, 1980, McGuire et al., 1989, 
Holmes et al., 1991, Murphy et al., 1993). A major debilitating side effect associated with 
paclitaxel treatment is peripheral neuropathy (Postma et al., 1995, Tamura et al., 1995). This 
neuropathy is characterized by sensory abnormalities indicative of both a loss and gain of 
sensory neuronal function (Wolfe and Trivedi, 2004) with symptoms that include numbness, loss 
of proprioception, tingling, burning pain and mechanical and cold hypersensitivity in the distal 
extremities of the hands and feet (Wiernik et al., 1987, Dougherty et al., 2004). The severity of 
neuropathic symptoms, which is dependent on factors including the single and cumulative dose, 
the number of treatment cycles and the patients’ medical history, often results in either a dose 
reduction or discontinuation of therapy (Postma et al., 1995, Hershman et al., 2011), and 
therefore compromises the successful treatment of cancer. While it is evident that paclitaxel 
alters sensory neuronal function, the exact mechanisms by which this occurs still remain 
unclear, and as a result, there are no current therapies to alleviate paclitaxel-induced peripheral 
neuropathy (PIPN). 
Animal models of PIPN have been established in an effort to study the effects of 
paclitaxel on sensory neuronal activity. In a low dose model, intraperitoneal injections of 
paclitaxel (1 mg/kg or 2 mg/kg) on four alternate days resulted in thermal, cold and mechanical 
hypersensitivity when assessed using behavioral testing; however, no overt structural nerve 
damage or toxicity was found to explain this hypersensitivity (Polomano et al., 2001, Flatters 
and Bennett, 2006). In contrast, in a higher dose model, paclitaxel (cumulative doses ranging 
from 32 mg/kg – 80 mg/kg) induced thermal hypoalgesia, suggesting a loss, rather than gain, of 
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function of the heat-responsive transient receptor potential vanilloid 1 (TRPV1) channel (Authier 
et al., 2000). Examining the effects of paclitaxel on neuronal sensitivity using a different 
functional end-point also showed loss of TRPV1 function following paclitaxel administration. 
Using vasodilation as an indirect measure of neuropeptide release, paclitaxel (cumulative dose 
4 mg/kg) decreased capsaicin-evoked vasodilation in the dermal skin layer (Gracias et al., 
2011). Such behavioral findings indicate that paclitaxel has dual effects on neuronal sensitivity 
which are dependent on the concentration and length of exposure to paclitaxel. Our laboratory 
has recapitulated similar effects of paclitaxel on sensory neuronal function in isolated dorsal root 
ganglia (DRG) sensory neurons. We found that a 5-day treatment with 10 nM paclitaxel 
increased capsaicin-evoked neuropeptide release whereas treatment with 300 nM decreased 
capsaicin-evoked release (Pittman et al., 2014). In this study, we questioned whether protein 
kinase C (PKC), a well-established modulator of TRPV1 channel function, was important for 
mediating the effects of paclitaxel on sensory neuronal function in isolated DRG cultures. 
Studies show that modulating the activity of conventional and novel protein kinase C 
isozymes (c/nPKC) alters the sensitivity of sensory neurons. In isolated DRG sensory neurons, 
exposure to phorbol esters, which activate c/nPKC, enhanced the release of the neuropeptide, 
calcitonin gene-related peptide (Supowit et al., 1995, Barber and Vasko, 1996), whereas 
downregulation of c/nPKC by chronic phorbol ester treatment attenuated capsaicin-evoked 
neuropeptide release (Barber and Vasko, 1996). It was also shown that activation of c/nPKC 
enhanced heat- and capsaicin-evoked currents in isolated DRG sensory neurons (Cesare et al., 
1999, Vellani et al., 2001, Zhou et al., 2001, Li et al., 2014) and increased calcium uptake via 
TRPV1 (Olah et al., 2002), thus c/nPKC play a large role in modulating the TRPV1 channel. 
 Recent studies have suggested that c/nPKC mediate enhanced neuronal sensitivity 
induced by paclitaxel. In rodent models, administration of PKCβII, PKCδ and PKCε inhibitory 
peptides reversed heat, cold and mechanical hypersensitivity induced by chronic administration 
of paclitaxel (Dina et al., 2001, Chen et al., 2011, He and Wang, 2015). In an acute in vitro 
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model, c/nPKC mediate an enhanced neuropeptide release following 10-30 minute exposures to 
paclitaxel in isolated DRG sensory neurons (Miyano et al., 2009, He and Wang, 2015). 
However, the onset of symptoms of peripheral neuropathy is typically 3-6 weeks following the 
first infusion of paclitaxel (Forsyth et al., 1997), and it is not known whether c/nPKC contribute to 
the maintenance of changes in neuronal sensitivity following chronic treatment with paclitaxel in 
sensory neurons. As such, we examined whether c/nPKC were responsible for changes in 
neuronal sensitivity induced by chronic treatment with paclitaxel (1-5 days) in isolated DRG 
sensory neurons. We found that paclitaxel attenuated phorbol ester- and capsaicin-stimulated 
peptide release in a conventional PKC-dependent manner. Under basal conditions, paclitaxel 
attenuated the activity of PKC α, βI and βII but had no effect on the protein expression, 
phosphorylation status or membrane localization. However, under stimulatory conditions, 
paclitaxel attenuated the activity of PKC α, βI and βII, as well as phorbol ester-stimulated 
membrane localization of phosphorylated PKC α, βI and βII. In conclusion, we demonstrated 
that PKCα and PKCβI/II were critical mediators of the reduction in capsaicin-stimulated 
neuropeptide release following chronic treatment with paclitaxel, thus implicating these 
isozymes in modulating the function of TRPV1 channels following paclitaxel treatment.  
 
2. Materials and Methods 
2.1. Sensory neuronal culture 
Dorsal root ganglia (DRG) were isolated and cultured as previously described (Pittman 
et al., 2014). Male Sprague Dawley rats (150-250 g, Envigo, Indianapolis, IN) were sacrificed by 
CO2 asphyxiation followed by decapitation. The DRG from all levels of the vertebral column 
were collected, trimmed and enzymatically digested in collagenase (0.125%; > 470 collagen 
digestion units) for 1 hour at 37°C. Using a small diameter fire-polished glass Pasteur pipette, 
DRG were mechanically dissociated in F-12 media supplemented with 10% heat-inactivated 
horse serum, 2 mM glutamine, 50 µg/mL penicillin and streptomycin, 50 μM 5-fluoro-2-
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deoxyuridine, 150 μM uridine and 30 ng/mL nerve growth factor. The neuronal cell suspension 
was plated on 12-well plates previously coated with poly-D-lysine and laminin to an approximate 
density of 30,000 cells per well. Neuronal cultures were maintained at 37°C with 3% CO2 
atmosphere. The media was changed every other day. For paclitaxel experiments, cultured 
sensory neurons were treated with 300 nM paclitaxel  for 1-5 days or 1 μM paclitaxel for 1-3 
days after 7 days in culture, as previously described (Pittman et al., 2014). All experiments were 
done in compliance with the Animal Care and Use Committee at Indiana University School of 
Medicine (Indianapolis, IN) and the National Institute of Health Guide for the Care and Use of 
Lab Animals. Prior to sacrifice, all animals were housed in group cages in a light controlled room 
with access to food and water ad libitum.  
 
2.2. Drug Stocks  
10 mM stocks of paclitaxel and 4-(3-Chloro-2-pyridinyl)-N-[4-(1,1-dimethylethyl)phenyl]-
1-piperazinecarboxamide (BCTC), and 1 mM stocks of phorbol 12,13-dibutyrate (PDBu), 4α-
PDBu, bisindolylmaleimide I (Bis I), Gö6976, LY333531 and Bis VIII were diluted in methyl-2-
pyrrolidone (MPL). The stock solutions were stored at -20°C and were further diluted in media or 
HEPES buffer to the desired concentrations for experiments.  
 
2.3. Calcitonin Gene-Related Peptide Release Assay 
CGRP release assays were performed on days 7-12 as previously described (Hingtgen 
and Vasko, 1994, Pittman et al., 2014) with slight modifications as follows. Briefly, neuronal 
cultures were washed with HEPES buffer (25 mM HEPES, 135 mM NaCl, 3.5 mM KCl, 2.5 mM 
CaCl2, 1 mM MgCl2, 3.3 mM D-glucose and 0.1 % bovine serum albumin, pH 7.4) followed by 
four sequential 10-minute incubations to assess the basal and stimulated release of 
immunoreactive calcitonin gene-related peptide (CGRP) under specific conditions. Neuronal 
cultures were maintained at 37°C with 3% CO2 atmosphere during the 10-minute intervals. For 
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the first and second interval, neuronal cultures were incubated with HEPES buffer +/- drug to 
establish basal release of CGRP. For the third interval, neuronal cultures were incubated with 
HEPES buffer containing 10 nM PDBu or 30 nM capsaicin +/- drug to stimulate the release of 
CGRP. For the fourth interval, neuronal cultures were incubated with HEPES buffer to re-
establish the basal release of CGRP. Neuronal cultures were incubated in 0.1N HCl for 20 
minutes at room temperature to release all remaining CGRP present in the neurons. The 
supernatant was collected after each interval and the amount of CGRP released into the 
supernatant was determined using radioimmunoassay, as previously described (Hingtgen and 
Vasko, 1994, Pittman et al., 2014). 
 
2.4. Western blotting 
Cells were scraped in F-12 media and transferred to eppendorf tubes. The sample was 
centrifuged at 14,000 rpm for 4 minutes and the supernatant was discarded. The cell pellet was 
washed in ice-cold sterile phosphate-buffered saline (PBS). The sample was then centrifuged at 
14,000 rpm for 4 minutes and the supernatant was discarded.  Modified RIPA lysis buffer 
containing 0.2 μg/mL phenylmethylsulfonyl fluoride (PMSF), 1 μg/mL pepstatin A, 1 mM sodium 
orthovanadate, 25 mM sodium fluoride, 0.1% sodium dodecyl sulfate and 200 μL/mL protease 
inhibitor cocktail (Roche Diagnostics) was added to the cell pellet. Following sonication, the 
protein concentration was determined using a Bio-Rad protein assay, based on the Bradford 
protein-dye binding method (Bradford, 1976). Equivalent amounts of whole cell lysate protein 
were separated on NuPAGE 4-12% Bis-Tris Gels and transferred to PVDF membranes. 
Membranes were incubated in a 5% dry milk Tris buffered saline (TBS) solution containing 1% 
Tween 20 (TBS-T) for 1 hour and incubated with primary antibodies diluted in 1% TBS-T 
overnight at 4°C. Primary antibodies included: mouse anti-PKCα (1:1000, Santa Cruz), rabbit 
anti-PKCβI (1:500, Santa Cruz), rabbit anti-PKCβII (1:1000, Santa Cruz), rabbit anti-
phospho(Ser) PKC substrate (1:1000, Cell Signaling Technology) and mouse anti-Actin (1:1000, 
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Thermo Fisher Scientific). Membranes were washed in 1% TBS-T and incubated in HRP-
conjugated secondary antibodies diluted in 1% TBS-T for 2 hours at room temperature. 
Secondary antibodies included: donkey anti-rabbit IgG-HRP (1:3000, Santa Cruz) and donkey 
anti-mouse IgG-HRP (1:3000, Thermo Fisher Scientific). The membranes were washed in 1% 
TBS-T. A Pierce ECL Western Blotting Substrate kit (Thermo Fisher Scientific) was used to 
detect immunoreactive bands on blue X-Ray films and the band density was quantified using 
KODAK 1D 3.6 (Scientific Imaging Systems, New Haven, CT).  
 
2.5. Isolation of Cytosolic and Membrane Protein Fractions 
The isolation of cytosolic and membrane protein fractions was done as previously 
described (Uehara et al., 2004) with slight modifications. The cell pellet was incubated in 
homogenization buffer (20 mM Tris-HCl pH 7.5, 330 mM sucrose, 0.5 mM EGTA, 2 mM EDTA, 
2 μg/mL aprotinin, 25 μg/mL leupeptin and 1 mM PMSF, 200 μL/mL protease inhibitor cocktail), 
homogenized with a polytron and centrifuged at 25,000 rpm for 35 minutes at 4°C. The 
supernatant was collected (cytosolic fraction) and the cell pellet (membrane fraction) was re-
suspended in homogenization buffer containing 1% Triton X-100 and placed on ice for 1 hour. 
The solution was centrifuged at 25,000 rpm for 35 minutes at 4°C. The resulting supernatant 
(membrane fraction) was collected. The protein concentrations of the cytosolic and membrane 
protein fractions were determined using the Bio-Rad protein assay and equivalent amounts of 
protein were separated on NuPAGE 4-12% Bis-Tris Gels. We then followed the Western blot 
protocol described above. In addition to the listed antibodies, primary antibodies included: 
mouse anti-p-PKCα (1:1000; Ser 657; Santa Cruz), rabbit anti-p-PKCβI (1:500; Thr 641; Santa 
Cruz), mouse anti-p-PKCβII/δ (1:1000; Ser 660; Santa Cruz) and rabbit anti-Na+/K+ ATPase α 
(1:1000, Cell Signaling Technology). 
 
2.6. Immunofluorescence and Membrane Translocation 
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Neuronal cultures were rinsed with phosphate-buffered saline (PBS) and fixed with 4% 
paraformaldehyde (PFA) for 20 minutes. The 4% PFA was aspirated and cells were rinsed with 
PBS and blocked in filtered blocking solution (normal donkey serum, Triton x-100 in 0.1M PBS, 
pH 6.0) for 1 hour. Cultures were incubated in a mixed pool of primary antibodies diluted in 
filtered blocking solution overnight at room temperature. Primary antibodies included: mouse 
anti-p-PKCα (1:500; Ser 657; Santa Cruz), rabbit anti-p-PKCβI (1:500; Thr 641; Santa Cruz) 
and mouse anti-p-PKCβII/δ (1:500; Ser 660; Santa Cruz). The following day, cells were rinsed 
with PBS and incubated with fluorescently labeled secondary antibodies diluted in filtered 
blocking solution for two hours at room temperature. Secondary antibodies included: Alexa 
Fluor 488 donkey anti-rabbit (1:200, Thermo Fisher Scientific) and Alexa Fluor 488 donkey anti-
mouse (1:200, Thermo Fisher Scientific). Cultures were rinsed in PBS and 1mL PBS was added 
to each well of the 12-well plate. Fluorescent images were acquired using the Leica DMI6000 B 
inverted microscope. To measure translocation of phospho-PKC α, βI and βII, five random fields 
of view were acquired for each treatment group and neurons were scored as positive or 
negative for membrane translocation and the data expressed as % of cells with phospho-PKC 
α/βI/βII translocation, as previously described (Ron et al., 1995, Gray et al., 1997).  
 
2.7. Reagents 
F-12 media, heat-inactivated horse serum, glutamine, penicillin, streptomycin, 5-fluoro-2-
deoxyuridine, uridine, NuPAGE 4-12% Bis-Tris Gels and PVDF membranes were obtained from 
Thermo Fisher Scientific (Waltham, MA). PDBu, Bis I, Gö6976 and BCTC were obtained from 
Tocris-BioTechne (Minneapolis, MN). The myristolyated PKCα/β peptide inhibitor (Myr-
RFARKGALRQKNV) and nerve growth factor were obtained from Promega (Madison, WI) and 
Envigo (Indianapolis, IN), respectively. 4α-PDBu and the RIPA lysis buffer were obtained from 
Santa Cruz (Dallas, Texas) and EMD Millipore (Billerica, MA), respectively. Bis VIII was 
obtained from Cayman Chemical (Ann Arbor, Michigan). The CGRP antibody was a kind gift 
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provided by Dr. M. Iadarola (National Institute of Health). All other reagents were purchased 
from Sigma Aldrich (St. Louis, MO).  
 
2.8. Statistical Analysis 
Data are represented as the mean ± standard error of mean (SEM). Data were analyzed 
by one-way analysis of variance (ANOVA) or two-way ANOVA and post-hoc tests were 
performed using either the Tukey’s or Dunnett’s multiple comparisions test using GraphPad 
Prism 7 software (La Jolla, CA) with p < 0.05 considered significant.  
 
3. Results  
3.1. Chronic treatment with paclitaxel decreases PDBu-stimulated CGRP release  
We previously showed that long-term treatment with paclitaxel (300 nM; 3 days and 5 
days) attenuated capsaicin-stimulated CGRP release in sensory neurons (Pittman et al., 2014).  
Because phorbol ester-induced activation of conventional and novel PKC isozymes (c/nPKC) 
increases TRPV1 activity (Vellani et al., 2001, Zhou et al., 2001, Numazaki et al., 2002, Bhave 
et al., 2003, Jeske et al., 2009), it is plausible that the attenuation in capsaicin-stimulated 
release upon treatment with paclitaxel is due to a loss of c/nPKC activity. To address this, we 
first examined the effects of treating sensory neuronal cultures with 300 nM or 1 µM paclitaxel 
for 1-5 days on the ability of phorbol 12, 13-dibutyrate (PDBu; 10 nM), a phorbol ester, to 
augment CGRP release. We expressed the data as % of total CGRP content since we have 
previously shown that changes in stimulated release following treatment with 300 nM paclitaxel 
for 3 days are not secondary to changes in peptide levels, and that treatment with 300 nM 
paclitaxel for 5 days does not alter CGRP content nor affect neuronal viability (Pittman et al., 
2014). We found that treatment with 300 nM paclitaxel attenuated PDBu-stimulated CGRP 
release in a time-dependent manner to 19.0 ± 1.9 (1 day), 11.8 ± 1.0 (3 days) and 7.7 ± 0.9% of 
total content (5 days) compared to vehicle-treated neurons (24.0 ± 1.3% of total content; 
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0.003% methylpyrrolidone (MPL); Figure 1A). Similar observations were made using a higher 
concentration of paclitaxel at shorter time intervals in which treatment with 1 µM paclitaxel 
attenuated PDBu-stimulated CGRP release to 12.2 ± 1.3 (1 day), 7.7 ± 1.2 (2 days) and 3.7 ± 
0.4% of total content (3 days) compared to vehicle-treated neurons (23.7 ± 0.4% of total 
content; 0.01% MPL; Figure 1B). These data indicate that chronic treatment with paclitaxel 
attenuates the release of CGRP evoked by PDBu-induced activation of c/nPKC isozymes.   
In addition to activation of c/nPKC, studies have reported that PDBu binds and activates 
other C1 domain-containing proteins (Colon-Gonzalez and Kazanietz, 2006) that have been 
implicated in neurotransmitter release (Betz et al., 1998). To confirm that CGRP release was 
due to a specific effect of PDBu to activate c/nPKC, neurons were pre-treated with 
bisindolylmaleimide I (Bis I), a selective inhibitor that competitively inhibits ATP binding in 
c/nPKC (Toullec et al., 1991), for 10 minutes prior to stimulation with 10 nM PDBu. Pre-
treatment with Bis I fully abolished PDBu-stimulated CGRP release from 14.1 ± 1.7 to 1.4 ± 
0.2% of total content (Figure 1C). There were no changes in basal release of CGRP (1.5 ± 0.1% 
of total content) compared to untreated neurons (1.1 ± 0.3% of total content) pre-treated with 
Bis I. Treatment with 10 nM 4α-PDBu, an inactive analog of PDBu that is incapable of activating 
c/nPKC (Silinsky and Searl, 2003), did not alter the release of CGRP (1.2 ± 0.2% of total 
content) compared to basal release (1.0 ± 0.2% of total content). These data indicate that PDBu 
stimulates the release of CGRP through the specific activation of c/nPKC.  
 
3.2. Chronic treatment with paclitaxel inhibits the activity of conventional PKC isozymes, 
α and βI/II, to elicit a decrease in PDBu-stimulated CGRP release  
Since PDBu is a direct activator of both conventional and novel PKC isozymes, we first 
wanted to determine which class of PKC isozymes mediates the increase in CGRP release 
evoked by PDBu in the absence of paclitaxel. To differentiate between the two classes of PKC 
isozymes, neuronal cultures were pre-treated with Gö6976, an ATP competitive inhibitor that is 
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selective for conventional PKC isozymes (Martiny-Baron et al., 1993), prior to stimulation with 
10 nM PDBu. Pre-treatment with 100 nM Gö6976 attenuated PDBu-stimulated release from 
11.3 ± 0.7 (control neurons) to 3.4 ± 0.2% of total content (Figure 2A), suggesting that 
conventional PKC isozymes, and not novel PKC isozymes, mediate PDBu-stimulated CGRP 
release. Having identified the class of PKC isozymes, we wanted to narrow down which specific 
isozymes mediate PDBu-stimulated release of CGRP. We investigated the specific contribution 
of PKCα and PKCβI/II versus PKCγ by pre-treating neuronal cultures with a myristolyated 
PKCα/β peptide inhibitor, prior to stimulation with 10 nM PDBu. The PKCα/β peptide, which is 
derived from a homologous sequence within the pseudosubstrate region of PKCα, PKCβI and 
PKCβII, consists of Ala25 in place of a phosphorylatable Ser/Thr and binds to the PKC substrate 
binding cavity to maintain the kinase in an inactive conformation (House and Kemp, 1987, 
Eichholtz et al., 1993). The activity of PKCγ, a conventional PKC isozyme, is unaffected by this 
peptide due to sequence dissimiliarities. Pre-treatment with 10 µM PKCα/β peptide inhibitor 
attenuated PDBu-stimulated CGRP release from 11.3 ± 0.7 (control neurons) to 3.5 ± 0.3% of 
total content (Figure 3A). There was no significant difference between basal (2.8 ± 0.2% of total 
content) and PDBu-stimulated release (3.5 ± 0.2% of total content) in the presence of the 
PKCα/β peptide inhibitor (Figure 2A). These data indicate that conventional PKC isozymes, α, 
βI and βII, mediate PDBu-stimulated release of CGRP.  
We next examined the relative contribution of PKCα and PKCβI/II in PDBu-stimulated 
release in the absence and presence of paclitaxel using small molecule inhibitors of these 
kinases. We chose to use selective small molecule inhibitors of PKCα and PKCβI/II, as opposed 
to the PKCα/β peptide inhibitor, as this would allow us to later discern the effects of each 
individual kinase. Cultured sensory neurons were treated with 300 nM paclitaxel for 3 days and 
pre-treated with a combination of PKCα (Bis VIII) and PKCβI/II (LY333531) inhibitors prior to 
stimulation with 10 nM PDBu; inhibitor concentrations used were based on reported values in 
the literature (Wilkinson et al., 1993, Jirousek et al., 1996, Zhou et al., 2006, Gray et al., 2013). 
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In vehicle-treated neurons, combined pre-treatment with 53 nM Bis VIII and 30 nM LY333531 
significantly attenuated PDBu-stimulated release from 11.5 ± 1.1 (vehicle-only) to 2.5 ± 0.2 % of 
total content (Figure 2B), confirming our earlier findings that PKC isozymes, α, βI and βII, 
mediate PDBu-stimulated CGRP release (see Figure 2A). In the presence of combined 
inhibition of PKCα and PKCβI/II, there was no further decrease in PDBu-stimulated release in 
paclitaxel-treated neurons (2.3 ± 0.2% of total content; Figure 2B) compared to vehicle-treated 
neurons (2.5 ± 0.2% of total content), suggesting that PKCα and PKCβI/II signal through 
common pathways. These data demonstrate that inhibition of PKCα and PKCβI/II activity is 
responsible for the reduction in CGRP release induced by paclitaxel.  
To differentiate between the individual contributions of PKCα and PKCβI/II, cultured 
sensory neurons were treated with 300 nM paclitaxel for 3 days and pre-treated with either Bis 
VIII or LY333531 prior to stimulation with 10 nM PDBu. In vehicle-treated neurons, we found 
that individual pre-treatment with either Bis VIII or LY333531 partially attenuated PDBu-
stimulated release to similar extents (Figures 2C and 2D), but did not completely block the 
increase in release as observed following combined pre-treatment with both inhibitors (see 
Figure 2B). This suggests that both PKCα and PKCβI/II are necessary to elicit an increase in 
CGRP release induced by PDBu; the single activity of either kinase is not sufficient to reach the 
given threshold. In the presence of paclitaxel, however, individual pre-treatment with Bis VIII 
(Figure 2C) and LY333531 (Figure 2D) resulted in a further significant reduction of PDBu-
stimulated release. Based on the findings in Figure 2B, these results suggest that the additional 
reduction in release from paclitaxel-treated neurons following inhibition of PKCα is due to the 
residual activity of PKCβI/II (Figure 2C); likewise, the additional reduction in release following 
inhibition of PKCβI/II is due to the residual activity of PKCα (Figure 2D). Overall, these sets of 
data suggest that inhibition of both PKCα and PKCβI/II activity, as oppsosed to inhibition of a 
single kinase, is responsible for reduction in CGRP release induced by paclitaxel. As such, the 
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two kinases share a common signaling pathway to elicit changes in sensory neuronal function 
following chronic treatment with paclitaxel. 
 
3.3. Chronic treatment with paclitaxel decreases the basal activity of conventional PKC 
isozymes, α and βI/II, as indicated by a reduction in the phosphorylation of cPKC 
substrates  
Researchers measure PKC activity by examining the phosphorylation of downstream 
PKC substrates (Numazaki et al., 2002, Zhang et al., 2002, Bhave et al., 2003, Ferreira et al., 
2005, Mandadi et al., 2006, Jeske et al., 2009). To determine whether paclitaxel altered the 
basal activity of PKC, neuronal cultures were treated with 300 nM paclitaxel for 3 or 5 days and 
the phosphorylation of PKC substrates was determined using an anti-phospho (Ser) PKC 
substrate antibody. This antibody recognizes PKC substrates when phosphorylated at serine 
residues surrounded by arginine or lysine at positions -2 and +2 and a hydrophobic residue at 
+1. Studies show that PKC isozymes can be distinguished from one another based on their 
substrate sequence motif (Nishikawa et al., 1997). All PKC isozymes select for substrates with a 
hydrophobic residue (i.e. Phe) at +1 and basic residues at -6, -4, -2, however, conventional PKC 
isozymes (α, βI, βII, and γ) and the novel PKC isozyme (η) have been shown to have higher 
selectivity for substrates with basic residues (i.e. arginine and lysine) at positions +2 and +3 
(Nishikawa et al., 1997). We found that treatment with 300 nM paclitaxel for 3 and 5 days 
decreased the phosphorylation of cPKC substrates (Figure 3A). These data strongly indicate 
that paclitaxel decreases the activity of cPKC with subsequent decreases in the phosphorylation 
of downstream cPKC substrates. As a positive control, neuronal cultures were treated with the 
c/nPKC activator, PDBu (100 nM and 1 μM), for 5, 10 or 30 minutes and the phosphorylation of 
cPKC substrates was determined using the anti-phospho (Ser) PKC antibody. As expected, 
treatment with PDBu, at all tested concentrations and time-points, increased phosphorylation of 
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cPKC substrates (Figure 3B), confirming that phorbol ester-induced activation of PKC enhances 
the phosphorylation of cPKC substrates in this assay.  
 
3.4. Chronic treatment with paclitaxel does not decrease the basal protein expression of 
conventional PKC isozymes, α, βI or βII 
To ascertain whether the decrease in CGRP release induced by paclitaxel is due to a 
reduction in the basal protein expression of PKC α, βI and/or βII, cultured sensory neurons were 
treated with 300 nM paclitaxel for 3 days and the protein expression in whole cell lysates was 
determined using Western blots. For our studies, the term “basal” encapsulates the cellular 
environment of cells treated with paclitaxel in the absence of a stimulatory agent. Treatment 
with 300 nM paclitaxel for 3 days did not attenuate the expression of PKCα (1.0 ± 0.1 arbitrary 
units; Figures 4A and 4B), PKCβI (1.6 ± 0.4 a.u.; Figures 4C and 4D) or PKCβII (1.1 ± 0.1 a.u.; 
Figures 4E and 4F) compared to vehicle (1.0 ± 0.0 a.u.). These findings suggest that changes in 
neuronal sensitivity induced by paclitaxel cannot be explained by a reduction in protein levels of 
the conventional PKC isozymes, α, βI and βII. 
 
3.5. Chronic treatment with paclitaxel does not attenuate the basal phosphorylation or 
membrane localization of conventional PKC isozymes, α, βI or βII 
The phosphorylation status and localization of conventional PKC isozymes (cPKC) are 
important determinants of cPKC activity. Lack of phosphorylation at three conserved 
phosphorylation sites in the catalytic domain predisposes PKC for degradation (Gould and 
Newton, 2008) and membrane translocation upon cPKC activation serves to position cPKC in 
close proximity to their downstream substrates (Mochly-Rosen and Gordon, 1998, Jaken and 
Parker, 2000).  To determine whether loss of phosphorylation or membrane localization under 
basal conditions accounted for the reduction of PDBu-stimulated CGRP release induced by 
paclitaxel, neuronal cultures were treated with 300 nM paclitaxel for 3 days and differential 
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centrifugation assays were performed to isolate the cytosolic and membrane protein fractions. 
Actin and Na+/K+ ATPase α were used as loading controls for cytosolic and membrane protein 
fractions, respectively. Treatment with 300 nM paclitaxel for 3 days did not significantly alter the 
levels of phosphorylated PKCα in the cytosol (1.04 ± 0.1 a.u.) or membrane (1.48 ± 0.7 a.u.) 
compared to vehicle-treated neurons (1.00 ± 0.0 a.u.; Figures 5A and 5B). There also were no 
significant differences in total PKCα in the cytosol (1.07 ± a.u.) or membrane (0.98 ± a.u.) 
following treatment with paclitaxel compared to vehicle-treated neurons (1.00 ± 0.0 a.u.; Figures 
5A and 5B). Similarly, treatment with 300 nM paclitaxel for 3 days did not significantly alter the 
levels of phosphorylated PKCβI in the cytosol (1.24 ± 0.0 a.u.) or membrane (1.71 ± 0.4 a.u.) or 
total PKCβI in the cytosol (1.15 ± 0.1 a.u.) or membrane (1.41 ± 0.3 a.u.) following treatment 
with paclitaxel compared to vehicle-treated neurons (1.00 ± 0.0 a.u.; Figures 5C and 5D). There 
also were no significant differences in phosphorylated PKCβII in the cytosol (1.15 ± 0.2 a.u.) or 
membrane (0.96 ± 0.1 a.u.) or total PKCβII in the cytosol (1.16 ± 0.1 a.u.) or membrane (0.89 ± 
0.2 a.u.) following treatment with paclitaxel (300 nM, 3 days) compared to vehicle-treated 
neurons (1.00 ± 0.0 a.u.; Figures 5E and 5F). These data indicate that under basal conditions, 
chronic treatment with paclitaxel does not alter the phosphorylation status of PKC α, βI, or βII 
demonstrating that these isozymes are stable and catalytically competent. We also show that 
paclitaxel does not alter the membrane localization of PKC α, βI, or βII under basal conditions.  
 
3.6. Chronic treatment with paclitaxel inhibits PDBu-stimulated membrane localization of  
conventional PKC isozymes, α, βI or βII 
We demonstrated that chronic treatment with paclitaxel does not alter the membrane 
localization of phosphorylated PKC α, βI, or βII under basal conditions. However, activation of 
PKC and subsequent membrane translocation and localization at cellular membranes is a short-
lived transient response (Cesare et al., 1999, Gould and Newton, 2008).  Although we did not 
detect paclitaxel-induced changes in membrane localization under basal conditions, the 
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sensitivity of the translocation assay is too low to detect minor shifts in PKC localization.  It was 
therefore important for us to ascertain whether chronic treatment with paclitaxel altered 
membrane translocation of phosphorylated PKC α, βI and βII following acute PDBu-induced 
activation of PKC. Cultured neurons were treated with 300 nM paclitaxel for 3 days or 5 days, 
and stimulated with 300 nM PDBu for 2 minutes. The changes in phosphorylated PKC α, βI and 
βII localization at the plasma membrane were determined using immunofluorescence in which 
neurons where stained with a pool of fluorescently labeled PKC α, βI, and βII antibodies. 
Studies have previously shown that PDBu-induced activation of c/nPKC increases membrane 
translocation of c/nPKC (Tsutsumi et al., 1993, Cesare et al., 1999, Zhu et al., 2007). Similarly, 
we demonstrate that treatment with 300 nM PDBu for 2 minutes increased the number of 
neuronal cell bodies which exhibit membrane localization of phosphorylated PKC α, βI, and βII 
from 0.0 ± 0.0 to 31.6 ± 3.0% (Figure 6A and 6B). However, treatment with 300 nM paclitaxel for 
3 days and 5 days decreased the percentage of cells with membrane localized phosphorylated 
PKC α, βI and βII to 13.7 ± 5.0 and 16.8 ± 8.0%, respectively (Figure 6A and 6B). Neither 3 day 
nor 5 day treatment with paclitaxel altered the percentage of cells with membrane localized 
phosphorylated PKC α/βI/βII under basal conditions (Figure 6A and 6B), confirming our findings 
in Figures 5A-E. These data indicate that paclitaxel attenuates the membrane localization of 
phosphorylated PKC α, βI and βII under stimulatory conditions and demonstrates that the loss 
of functional PKC effects could be due to misdirected cPKC localization. 
 
3.7. Chronic treatment with paclitaxel inhibits the activity of conventional PKC isozymes, 
α and βI/II, to elicit a decrease in capsaicin-stimulated CGRP release  
It is well-established that the function of TRPV1 channels is modulated by conventional 
and novel PKC isozymes (c/nPKC). Studies have shown that phorbol-ester induced activation of 
c/nPKC enhanced the phosphorylation of TRPV1 channels (Jeske et al., 2009) and augmented 
capsaicin-induced currents in sensory neurons (Vellani et al., 2001, Zhou et al., 2001), whereas 
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downregulation of c/nPKC by chronic phorbol ester treatment attenuated capsaicin-stimulated 
CGRP release (Barber and Vasko, 1996). Furthermore, there is strong evidence to support that 
PDBu-induced CGRP release is mediated by TRPV1 activation in spinal cord tissue (Mogg et 
al., 2013). In these studies, it was shown that PDBu- and capsaicin-stimulated CGRP release 
was attenuated following pre-treatment with multiple TRPV1 antagonists (BCTC, AMG517, 
A425619, A784168, AMG 49a, AMG9810, JNJ 17203212, SB705498, Neurogen) and was also 
blocked in spinal cord tissue from TRPV1 null mutant mice (Mogg et al., 2013).  
To assess whether PDBu-stimulated release was dependent on TRPV1 channels in 
cultured sensory neurons,  cultured sensory neurons were pre-treated with increasing 
concentrations of the TRPV1 antagonist, 4-(3-Chloro-2-pyridinyl)-N-[4-(1,1 
dimethylethyl)phenyl]-1-piperazinecarboxamide (BCTC), for 10 minutes prior to stimulation with 
10 nM PDBu. Pre-treatment with 1 nM BCTC significantly attenuated PDBu-stimulated release 
from 9.2 ± 1.2 to 2.3 ± 0.5% of total content (Figure 7A); neither 0.01 nM nor 0.1 nM BCTC 
altered PDBu-stimulated release. The basal release following pre-treatment with 0.01 nM (0.8 ± 
0.1), 0.1 nM (1.2 ± 0.1) and 1 nM BCTC (0.9 ± 0.1% of total content) was not significantly 
different when compared to control (0.7 ± 0.1% of total content; Figure 7A). These findings 
indicate that PDBu-stimulated release is mediated by activation of TRPV1 channels. 
Since our previous studies demonstrated that chronic treatment with paclitaxel (300 nM; 
3 and  5 days) attenuates capsaicin-stimulated peptide release (Pittman et al., 2014), we 
wanted to ascertain whether conventional PKCα and PKCβI/II were responsible for the changes 
in capsaicin-stimulated CGRP release following chronic treatment with paclitaxel. Cultured 
sensory neurons were treated with 300 nM paclitaxel for 5 days and pre-treated with the 
myristolyated PKCα/β peptide inhbitior (10 μM) for 10 minutes prior to stimulation with 30 nM 
capsaicin. Treatment with paclitaxel significantly attenuated capsaicin-stimulated release from 
21.1 ± 1.5 (vehicle-only) to 17.6 ± 1.0% of total content (Figure 7B), confirming our previous 
findings (Pittman et al., 2014). Pre-treatment with the PKCα/β peptide inhibitor in vehicle-treated 
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neurons significantly attenuated capsaicin-stimulated release to 7.9 ± 1.0% of total content 
compared to vehicle-only treated neurons, suggesting that a major component of capsaicin-
stimulated release is due to PKC α, βI and βII. However, pre-treatment with the PKCα/β peptide 
inhibitor did not significantly alter capsaicin-stimulated release in paclitaxel-treated neurons (6.0 
± 0.7% of total content) compared to vehicle-treated neurons (7.9 ± 1.0% of total content; Figure 
7B), suggesting that paclitaxel inhibits that activity of PKCα and PKCβI/II to elicit a decrease in 
capsaicin-stimulated peptide release.  
 We next verified whether inhibition of PKCα and PKCβI/II activity mediates loss of 
PDBu-stimulated release following treatment with 300 nM paclitaxel for 5 days, as demonstrated 
using the 3-day treatment paradigm. Treatment with 300 nM paclitaxel for 5 days significantly 
attenuated PDBu-stimulated release from 12.2 ± 1.1 (vehicle-only) to 9.1 ± 0.9% of total content 
(Figure 7C), in a manner analogous to that observed with the 3 day treatment (see Figures 2B-
D). As expected, pre-treatment with the 10 μM myristolyated PKCα/β peptide inhibitor 
completely abolished PDBu-stimulated release; PDBu-stimulated release decreased from 12.2 
± 1.1 (vehicle-only) to 4.7 ± 0.4% of total content (Figure 7C). Pre-treatment with the PKCα/β 
peptide inhibitor did not significantly alter PDBu-stimulated release in paclitaxel-treated neurons 
(5.2 ± 0.4% of total content) compared to vehicle-treated neurons (4.7 ± 0.4% of total content; 
Figure 7C). These findings are analgous to that observed following combined pre-treatment with 
the PKCα and PKCβI/II inhibitors, Bis VIII and LY333531, following treatment with paclitaxel for 
3 days (see Figure 2B). Similar to the 3-day paclitaxel treatment paradigm, a more prolonged 
exposure to paclitaxel decreases the activity of PKCα and PKCβI/II to elicit an attenuation in the 
stimulated release of CGRP. 
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4. Discussion  
Our work indicates that PKCα and PKCβI/II are critical mediators of changes in neuronal 
sensitivity in TRPV1 positive sensory neurons following chronic exposure to paclitaxel. Using 
isolated sensory neurons, we show that chronic treatment with paclitaxel inhibits the activity of 
PKCα and PKCβI/II and the membrane localization of phosphorylated PKCα and PKCβI/II to 
elicit a reduction in the stimulated release of neuropeptide from capsaicin-sensitive neurons. 
These findings provide a mechanistic understanding of the effects of chronic exposure to 
paclitaxel on sensory neuronal function.  
To determine the effects of paclitaxel on PKC-modulation of sensory neurons, our model 
relied upon measuring changes in neuropeptide release following stimulation with the phorbol 
ester, PDBu, in cultured sensory neurons. PDBu is a potent stimulator of CGRP release from 
sensory neurons, however it is evident from our experiments that the levels of release are 
variable among different release assay experiments. These differences in release can be 
explained by very slight differences in cell density. There is an approximate density of 30,000 
cells per well, however, slight differences in the cell density will affect the total content of CGRP 
per well. To control for these differences, each individual experiment consisted of vehicle-
treated (control) neurons. Furthermore, the data was normalized to the total content of CGRP 
per well.  
PKC isozymes are differentially expressed in various cell types, exhibit differential 
sensitivity to calcium, and interact with different substrates (Way et al., 2000). It was imperative 
for us to first ascertain which class of PKC isozymes was responsible for the actions of PDBu on 
neuropeptide release. Pharmacological manipulation is limited by narrow ranges of 
concentration at which many of the small molecule inhibitors demonstrate selectivity for a given 
PKC isozyme. Therefore, in addition to using multiple small molecule inhibitors, we also used a 
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myristoylated PKCα/β peptide inhibitor to discern the contribution of specific isozymes. We did 
not employ a genetic approach to modulate PKC expression due to the propensity for PKC 
isozyme compensation and PKC cross-modulation of sub-cellular localization of other isozymes 
(Collazos et al., 2006). Pre-treatment with 100 nM Gö6976, a selective inhibitor of conventional 
PKC isozymes (cPKC) significantly reduced PDBu-stimulated release. Studies have shown that 
concentrations up to 3 M selectively inhibit cPKC while having no effect on the activity of novel 
PKC isozymes (Martiny-Baron et al., 1993), therefore our findings indicate that novel PKC 
isozymes are not involved in mediating PDBu-stimulated neuropeptide release from isolated 
sensory neurons. Using the PKCα/β peptide inhibitor, which consists of a sequence derived 
from homologous regions within the pseudosubstrate of PKC isozymes α, βI and βII (House and 
Kemp, 1987, Eichholtz et al., 1993), we were able to further isolate and examine the 
contributions of specific conventional PKC isozymes. The PKCα/β peptide inhibitor does not 
alter the activity of PKCγ due to differences in amino acid sequences, therefore allowing us to 
specifically examine the contributions of PKCα and PKCβI/II. Pre-treatment with the PKCα/β 
peptide inhibitor fully abolished PDBu-stimulated release indicating that PKCα and PKCβI/II 
were responsible for mediating the actions of PDBu. These findings were substantiated using a 
combined pre-treatment with selective small molecule inhibitors of PKCα (Bis VIII) and PKCβI/II 
(LY333531). Importantly, in paclitaxel-treated neurons, combined pre-treatment with PKCα (Bis 
VIII) and PKCβI/II (LY333531) inhibitors and pre-treatment with the PKCα/β peptide inhibitor, did 
not further alter PDBu-stimulated release, suggesting that loss of PKCα and PKCβI/II activity 
was responsible for the loss of neuronal sensitivity induced by paclitaxel. In addition to the use 
of selective PKCα  and PKCβI/II inhiibitors, we demonstrated that paclitaxel has a direct effect 
on the activity of cPKC using an antibody that recognizes the phosphorylated levels of cPKC 
substrates. We showed that paclitaxel decreased the phosphorylated levels of cPKC substrates, 
therefore indicating loss of cPKC activity. Our data shows that PKCα and PKCβI/II are the major 
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components of PDBu-evoked neuropeptide release, and that paclitaxel inhibits the activity of 
these kinases to elicit a reduction in neuronal sensitivity.  
In addition to modulating the activity of cPKC, it is plausible that paclitaxel alters the 
basal expression, phosphorylation status and/or localization of cPKC. The term “basal”  is used 
to describe the cellular environment of cells that were treated with paclitaxel for days, but were 
not exposed to a stimulatory agent. We first investigated whether paclitaxel modulated total 
cPKC protein levels under basal conditions. A reduction in cPKC protein levels could provide an 
explanation for the loss in neuropeptide release induced by chronic treatment with paclitaxel 
since PDBu-stimulated release is dependent on PKC activity, however, we observed no 
changes in the total protein levels of either PKC α, βI or βII. While total cPKC levels remained 
unchanged, it was plausible that paclitaxel attenuated the phosphorylated levels of cPKC and/or 
inhibited the localization of phosphorylated cPKC at cellular membranes under basal conditions. 
Studies have shown that phosphorylation of residues in the kinase domain, turn motif and 
hydrophobic motif, are required for catalytic competence and stability of PKC (Shirai and Saito, 
2002, Gould and Newton, 2008) whereas a lack of phosphorylation predisposes the protein to 
undergo degradation via the ubiquitin-proteasome pathway (Lu et al., 1998, Gould and Newton, 
2008). Following activation, phosphorylated cPKC translocate from the cytosol to cellular 
membranes positioning them in close proximity to membrane-bound substrates involved in 
altering neuronal sensitivity. We found that paclitaxel did not decrease the degree of 
phosphorylation of either PKC α, βI or βII in the cytosolic or membrane fractions under basal 
conditions. Studies examining the acute (10 minutes -1 hour) effects of paclitaxel have 
demonstrated enhanced membrane localization of conventional PKC isozymes in cultured DRG 
sensory neurons (He and Wang, 2015). Another investigator found that treatment with paclitaxel 
for 2-10 minutes also enhanced translocation of PKCβ, using a pan PKCβ antibody, to the 
membrane fraction while having no effect on PKCα localization (Miyano et al., 2009). It is 
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apparent that acute exposure to paclitaxel enhances the translocation of PKCβII to cellular 
membranes, however, membrane localization of PKCβII is not maintained following chronic 
exposure to paclitaxel under basal conditions. Given the physiological nature of PKC membrane 
localization, it is somewhat unsurprising that we did not observe any effects on cPKC 
translocation following chronic treatment with paclitaxel under basal conditions. PKC localization 
at cellular membranes upon activation is a short-lived response (Cesare et al., 1999, Gould and 
Newton, 2008). In fact, prolonged localization of activated PKC at cellular membranes results in 
downregulation of PKC (Gould and Newton, 2008). Having determined that cPKC was not 
downregulated, it became apparent that our experimental design examining changes in 
phosphorylated cPKC localization under basal conditions was not sensitive enough to detect 
small changes in PKC localization, given the temporal nature of PKC activation and the potential 
short time intervals of membrane localization. Therefore, to better understand the effects of 
chronic paclitaxel treatment on membrane localization of phosphorylated cPKC, neurons treated 
with paclitaxel were stimulated acutely (2 minutes) with PDBu and the percentage of cells that 
exhibited cPKC membrane localization was determined. We demonstrated that chronic 
treatment with paclitaxel decreased phorbol ester-stimulated membrane localization of 
phosphorylated PKC α, βI and βII. The observation that chronic treatment with paclitaxel (under 
basal conditions) decreased cPKC substrate phosphorylation while having no effects on 
phosphorylated cPKC membrane localization highlights the temporal nature of PKC signaling. 
We believe that the effects of paclitaxel on cPKC substrate phosphorylation is a composite of 
phosphorylation events over time. On the other hand, because of the short-lived nature of cPKC 
membrane localization, changes in membrane translocation of phosphorylated PKC after 
chronic treatment with paclitaxel would be undetectable in the absence of an acute stimulus to 
activate PKC.  
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 There is precedence in the literature to support that the activation of PKC differentially 
alters membrane ion channel function via phosphorylation. Studies have found that N- and L-
type calcium currents are enhanced following activation of PKC whereas sodium currents are 
attenuated (Yang and Tsien, 1993, Hall et al., 1995, Chen et al., 2005). Notably, the activity of 
the nociceptive ligand-gated TRPV1 ion channel (Caterina et al., 1997) is also modulated by 
PKC phosphorylation. Under physiological conditions, PKC dependent phosphorylation of 
TRPV1 occurs downstream of Gq coupled receptor activation by inflammatory substances such 
as bradykinin (Cesare et al., 1999, Sugiura et al., 2002). Studies have shown that enhancing 
PKC activity, either via phorbol ester activation or via overexpression of a constitutively active 
PKCε construct, potentiates capsaicin- and heat-activated TRPV1 currents (Cesare et al., 1999, 
Numazaki et al., 2002, Bhave et al., 2003) whereas downregulation of PKCα following chronic 
treatment with PDBu attenuates PDBu-stimulated calcium uptake in NIH 3T3 cells expressing 
TRPV1 (Olah et al., 2002). More recently, it was found that PKCβII phosphorylation of TRPV1 
increased the sensitivity of the channel (Li et al., 2014). Unlike PKCε, a novel PKC isozyme 
which is believed to be positioned in close proximity to TRPV1 through A-kinase anchoring 
protein 150 (Jeske et al., 2009), PKCβII directly binds to TRPV1 to alter its function (Li et al., 
2014).  
Our previous studies have shown that paclitaxel has concentration- and time-dependent 
effects on TRPV1 function in cultured sensory neurons. Treatment with 300 nM paclitaxel for 5 
days decreased capsaicin-stimulated release, whereas treatment with lower concentrations (10 
nM) increased capsaicin-stimulated release (Pittman et al., 2014). Using our in vitro culture 
system, we recapitulated the gain and loss of TRPV1 function that is observed in animal models 
of paclitaxel-induced peripheral neuropathy (Campana et al., 1998, Authier et al., 2000, Chen et 
al., 2011, Gracias et al., 2011, Hara et al., 2013, Li et al., 2015). In this manuscript, we chose to 
focus on the importance of PKC in the loss of TRPV1 function in neurons treated with 300 nM 
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paclitaxel for 3 or 5 days. However, we do speculate that PKC has a role in the gain of TRPV1 
function upon chronic treatment with paclitaxel since treatment with 10 nM paclitaxel for 3 days 
increased PDBu-stimulated peptide release in cultured sensory neurons (data not shown). 
Given the numerous studies implicating PKC in modulating TRPV1 function, it was unsurprising 
that we found a significant attenuation of capsaicin-evoked release upon pre-treatment with the 
myristolyated PKCα/β peptide inhibitor. These findings strongly demonstrate that neuropeptide 
release upon TRPV1 activation is largely mediated by PKCα and PKCβI/II in isolated sensory 
neurons. Our additional studies in paclitaxel-treated neurons show that the reduction in 
capsaicin-stimulated release is due to loss of PKCα and PKCβI/II activity. We speculate that 
paclitaxel-induced inhibition of PKCα and PKCβI/II activity causes a decrease in TRPV1 
phosphorylation resulting in a subsequent reduction of neuropeptide release. Such reasoning 
could provide a plausible explanation for the loss of TRPV1 function observed following chronic 
exposure to paclitaxel. Another possible explanation for the reduction in capsaicin-stimulated 
release is the desensitization of TRPV1 channels. Various signaling proteins have been 
implicated in regulating the desensitization of TRPV1 channels. Activation of protein kinase A 
(PKA) and inhibition of the phosphatase, calcineurin, have both been shown to reduce 
capsaicin-induced TRPV1 desensitization (Mohapatra and Nau, 2003, 2005, Por et al., 2010, 
Sanz-Salvador et al., 2012). Unlike with PKA and calcineurin, there has been conflicting data 
regarding the role of PKC in TRPV1 desensitization. It was found that phorbol ester-induced 
activation of PKC reversed TRPV1 desensitization in a calcium-dependent manner, whereas 
inhibition of PKC, using an inhibitory peptide, prevented the recovery of TRPV1 sensitization 
(Mandadi et al., 2004, Mandadi et al., 2006). While these findings oppose the observations of 
others who found no involvement of PKC in the reversal of TRPV1 desensitization (Mohapatra 
and Nau, 2003, 2005), these studies suggest the decrease in capsaicin-stimulated release 
following chronic exposure to paclitaxel could be attributable to a loss in the recovery of 
desensitized TRPV1 channels via decreased activity of PKC. Although not within the scope of 
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this work, future studies will examine the mechanism by which loss of PKC activity alters TRPV1 
function.  
The observed loss of TRPV1 function in isolated sensory neurons is analogous to 
findings in in vivo models of paclitaxel-induced peripheral neuropathy. It was shown that 
systemic injections of paclitaxel (cumulative doses ranging between 18 and 80 mg/kg) induced 
thermal hypoalgesia (Campana et al., 1998, Authier et al., 2000) and (4 mg/kg cumulative dose) 
attenuated capsaicin-evoked blood flow in the rat hindpaw (Gracias et al., 2011). These in vivo 
studies demonstrate that paclitaxel decreased the function of small diameter TRPV1-expressing 
neurons. Interestingly, a recent study found that the loss of peptidergic TRPV1-expressing 
sensory neurons unmasked cold hypersensitivity (McCoy et al., 2013), a major symptom of 
paclitaxel-induced peripheral neuropathy (Dougherty et al., 2004). Therefore, it is plausible that 
the observed loss of TRPV1 function following chronic treatment with paclitaxel enhances 
neuronal sensitivity to cold temperatures. In conjunction with our studies, the aforementioned 
findings highlight a possible physiological role for PKC α, βI and βII as critical regulators of hot, 
cold and mechanical sensitivity following chronic exposure to paclitaxel in patients.  
 In conclusion, our studies show that the conventional PKC isozymes, α, βI and βII, are 
critical mediators of changes in neuronal sensitivity following chronic treatment with paclitaxel. 
Chronic treatment with paclitaxel attenuated the activity and membrane localization of PKC α, βI 
and βII to elicit a reduction in stimulated peptide release from capsaicin-sensitive neurons.  
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Figure legends: 
Figure 1: Paclitaxel decreases PDBu-stimulated CGRP release in cultured sensory neurons. 
Each column represents the mean ± SEM of basal (white columns) or stimulated (black 
columns) CGRP release expressed as % of total content. Cultures were exposed to (A) 300 nM 
or (B) 1 μM paclitaxel for 1, 2, 3 or 5 days prior to stimulation with PDBu (10 nM). An * indicates 
a significant decrease in PDBu-stimulated release in paclitaxel-treated (300 nM and 1 μM) 
neurons compared to vehicle-treated neurons (p < 0.05, N = 7-9). (C) Naïve cultures were pre-
treated with Bis I (1 μM) for 10 minutes prior to stimulation with PDBu. As a control experiment, 
naïve cultures were also incubated with 10 nM 4α-PDBu (dotted columns). An * indicates a 
significant decrease in PDBu-stimulated release in neurons pre-treated with Bis I (p < 0.05, N = 
10). Significance was determined using a two-way ANOVA with Tukey’s post-hoc test. N.S. – 
not significant. 
 
Figure 2: Inhibition of PKCα and PKCβI/II activity mediates the decrease in PDBu-stimulated 
CGRP release following chronic exposure to paclitaxel in cultured sensory neurons. Each 
column represents the mean ± SEM of basal (white columns) or PDBu-stimulated (black 
columns) CGRP release expressed as % of total content in the absence and presence of PKCα 
and PKCβI/II inhibitors. (A) Naïve cultures were pre-treated with Gö6976 (100 nM) or a 
myristoylated PKCα/β peptide inhibitor (10 μM) for 10 minutes prior to stimulation with PDBu (10 
nM). An * indicates a significant decrease in PDBu-stimulated release in neurons pre-treated 
with Gö6976 or the myristoylated PKCα/β peptide inhibitor (p < 0.05, N = 12). Cultures were 
exposed to 300 nM paclitaxel for 3 days prior to stimulation with PDBu (10 nM) in the presence 
and absence of the (B) PKCα inhibitor (Bis VIII; 53 nM) + PKCβI/II inhibitor (LY333531; 30 nM), 
(C) Bis VIII or (D) LY333531. An * indicates a significant decrease in PDBu-stimulated release 
in paclitaxel-only treated neurons, vehicle- and paclitaxel-treated neurons pre-treated with (B) 
Bis VIII + LY333531, (C) Bis VIII or  (D) LY333531 compared to vehicle-only treated neurons 
and a # indicates a significant decrease in PDBu-stimulated release in paclitaxel-treated 
neurons compared to vehicle-treated neurons pre-treated with (C) Bis VIII or (D) LY333531. 
Significance was determined using a two-way ANOVA with Tukey’s post-hoc test (p < 0.05, N = 
8-12). Veh - Vehicle; Pac - Paclitaxel; LY333 - LY333531; N.S. – not significant. 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
Figure 3: Chronic treatment with paclitaxel decreases the basal phosphorylation of PKC α/β 
substrates in cultured sensory neurons. (A) Representative western blot image showing 
immunoreactivity for phosphorylation of PKC α, βI and βII substrates in whole cell lysates in 
neurons treated with vehicle and paclitaxel (300 nM, 3 and 5 days). (B) Representative western 
blot image showing immunoreactivity for phosphorylation of PKC α, βI and βII substrates in 
neurons treated with PDBu (100 nM and 1 μM; 5, 10 or 30 minutes). Veh - Vehicle; Pac – 
Paclitaxel; 3D – 3 days; 5D – 5 days. 
 
Figure 4: Chronic treatment with paclitaxel does not reduce basal PKC α, βI or βII, 
immunoreactivity in cultured sensory neurons. (A, C, E) Representative western blot images 
showing immunoreactivity for PKC α, βI and βII in whole cell lysates in neurons treated with 
vehicle and paclitaxel (300 nM, 3 days). (B, D, F) Densitometry analysis showing no significant 
differences in PKC immunoreactivity normalized to actin in paclitaxel-treated (300 nM, 3 days) 
neurons compared to vehicle-treated neurons using a t-test (N = 3-4, a.u. ± SEM). Veh - 
Vehicle; Pac -Paclitaxel. 
 
Figure 5: Chronic treatment with paclitaxel does not attenuate the basal phosphorylation level or 
membrane localization of PKC α, βI or βII in cultured sensory neurons. (A, C, E) Representative 
western blot images showing immunoreactivity for PKC α, βI and βII in cytosolic and membrane 
fractions of neurons treated with vehicle and paclitaxel (300 nM, 3 days). (B, D, F) Densitometry 
analysis showing no significant differences in PKC immunoreactivity in paclitaxel-treated (300 
nM, 3 days) neurons compared to vehicle-treated neurons in cytosolic and membrane fractions 
when normalized to actin and Na+/K+ ATPase α, respectively. Significance was determined 
using a two-way ANOVA with Tukey’s post-hoc test (N = 3-4, a.u. ± SEM). Veh - Vehicle; Pac -
Paclitaxel. 
 
Figure 6: Chronic treatment with paclitaxel decreases PDBu-stimulated membrane localization 
of PKC α, βI and βII in cultured sensory neurons. (A) Representative fluorescent images 
showing membrane localization of immunoreactive phosphorylated PKC α, βI and βII in neurons 
treated with paclitaxel (300 nM, 3 days or 5 days) following stimulation with PDBu (300 nM, 2 
minutes). (B) Graphical analysis showing the number of neuronal cell bodies demonstrating 
translocation of phosphorylated PKC α, βI and βII in paclitaxel-treated neurons (300 nM, 3 and 5 
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days) following stimulation with PDBu (300 nM, 2 minutes) expressed as % of phospho- PKC 
α/βI/II translocation. An * indicates a significant decrease in the number of cells with PKC α, βI 
and βII translocation. Significance was determined using a two-way ANOVA with Dunnett’s 
post-hoc test (p < 0.05, N = 3). Scale bar = 20 μm. Veh - Vehicle; Pac –Paclitaxel, 3D – 3 days, 
5D – 5 days.  
 
Figure 7: Inhibition of PKCα and PKCβI/II activity mediates the decrease in capsaicin-stimulated 
CGRP release following chronic exposure to paclitaxel in cultured sensory neurons. Each 
column represents the mean ± SEM of basal (white columns), capsaicin-stimulated (striped 
columns) or PDBu-stimulated (black columns) CGRP release expressed as % of total content. 
(A) Naïve cultures were pre-treated with the TRPV1 antagonist, BCTC, for 10 minutes prior to 
stimulation with capsaicin (30 nM). An * indicates a significant decrease in capsaicin-stimulated 
release in neurons pre-treated with BCTC compared to control neurons (p < 0.05, N = 7-9). 
Cultures were exposed to 300 nM paclitaxel for 3 days and pre-treated with a myristolyated 
PKCα/β peptide inhibitor (10 μM) for 10 minutes prior to stimulation with (B) 30 nM capsaicin or 
(C) 10 nM PDBu. An * indicates a decrease in (B) capsaicin-stimulated and (C) PDBu-
stimulated release in paclitaxel-only treated neurons, vehicle- and paclitaxel treated neurons 
pre-treated with the myristolyated PKCα/β peptide inhibitor compared to vehicle-only treated 
neurons. Significance was determined using a two-way ANOVA with Tukey‘s post-hoc test (p < 
0.05, N = 8-15). N.S. – not significant. 
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
Figure 1 
 
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
Figure 2 
 
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
Figure 3 
 
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
Figure 4 
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
Figure 5 
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
Figure 6 
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
Figure 7 
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
Highlights 
 Stimulated CGRP release was measured as an index of neuronal sensitivity. 
 Paclitaxel attenuates phorbol ester- and TRPV1-stimulated release. 
 Paclitaxel attenuates basal and stimulated cPKC activity.  
 Paclitaxel attenuates stimulated cPKC membrane translocation. 
 Paclitaxel does not affect basal cPKC expression, phosphorylation or localization. 
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